|Day Low/High||168.55 / 175.24|
|52 Wk Low/High||76.75 / 175.45|
Even more important than fiscal support moving forward would be the concept of Covid-19 very soon being effectively treatable for the public.
The short-term story for financial markets has been all about fiscal policy. This remains true.
The stock market is out of sync with the current economy, but it can be a forecasting machine. Let's see what it says.
Biotech is on fire right now, but these 3 stocks 'sleeper' stocks aren't yet overbought.
From small-cap genetics and biotech firms to large-cap drug distributors and pharmacies, eight experts select their top picks in the space for this year.
The president-elect's words rattled the sector, though Amgen appears to be shrugging off his remarks.
These stocks are down some 20% over the last 30 months and look ripe for a rise.
Only one fund category (of 20) has beaten the S&P 500 over half a decade.
I'm content to head into the weekend with my short-term book mostly on the cash side.